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In The New England Journal of Medicine, Paz-Ares and 
colleagues published the results of KEYNOTE-407, a 
randomized phase III placebo-controlled trial, investigating 
the addition of pembrolizumab or placebo to first-line 
carboplatin-taxane chemotherapy, in patients with advanced 
squamous non-small cell lung cancer (NSCLC) (1). The study 
met its co-primary end-points, since immune-chemotherapy 
combination led to a significant longer overall survival 
(OS) and progression-free survival (PFS) as compared to 
placebo combination. In the intention to treat population, 
the median OS was 15.9 vs. 11.3 months [hazard ratio (HR): 
0.64; 95% confidence interval (CI): 0.49 to 0.85], and the 
median PFS was 6.4 vs. 4.8 months (HR: 0.56; 95% CI: 
0.45 to 0.70). The addition of pembrolizumab to platinum-
chemotherapy resulted also in a significant increase of 1-year 
survival rate (65.2% vs. 48.3%), response rate (RR) (57.9% 
vs. 38.4%), and duration of response (7.7 vs. 4.8 months). 
The survival benefit was maintained in all subgroups of 
patients selected according to both clinical and pathological 
characteristics, including tumor programmed death ligand 
1 (PD-L1) expression level. As expected, the number of 
patients who experienced immune-related adverse events 
(irAEs) and infusion reactions was significantly higher 
with immunotherapy than placebo (28.8% vs. 8.6%), with 
grade 3 or higher AEs reported to be 10.8% vs. 3.2%, 
respectively. Finally, the percentage of AEs leading to 
the discontinuation of any treatment components nearly 
doubled with pembrolizumab compared to placebo.
These findings led to the immediate approval of first-line 
immune-chemotherapy combination for patients with 
metastatic squamous NSCLC by regulatory authorities (U.S. 
Food and Drug Administration on October 30th, 2018, and 
European Medical Agency on March 14th, 2019). This 
approval marks a relevant milestone in the treatment of this 
lung cancer histotype, which accounts for 25–30% of all 
NSCLC, is almost always smoking-induced and associated 
to the lack of actionable mutations, therefore very difficult 
to treat with systemic therapies (2). Since the majority of 
recent advances in lung cancer treatment, including new 
chemotherapy agents, like pemetrexed, and targeted 
therapies, have been limited to non-squamous subtype, 
platinum-based combinations remained for a long time the 
backbone upfront therapy for squamous NSCLC, reaching a 
median survival plateau of 10–11 months (3). Combining the 
epidermal growth factor receptor (EGFR) inhibitor 
necitumumab with platinum-gemcitabine led only to a small 
improvement of OS (from 9.9 to 11.5 months) with an 
overall 16% reduction in the risk of death in the randomized 
phase III SQUIRE trial (4). Although patients with high 
tumor EGFR protein expression by immunohistochemistry 
(IHC), or EGFR copy number gain by fluorescence in situ 
hybridization (FISH), seem to gain longer survival benefit, 
however a validated predictive biomarker has not been 
established yet for clinical use. More recently, the 
KEYNOTE-024 study clearly demonstrated that single 
agent pembrolizumab is more effective and better tolerated 
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than first-line platinum-based chemotherapy in non-
oncogene-addicted, metastatic NSCLC, with PD-L1 tumor 
proportion score of 50% or higher, reaching 30 months of 
median OS at the last follow-up (5), as compared to the 
14.2 months of chemotherapy (HR: 0.63, 95% CI: 0.47–
0.86). Following these results, pembrolizumab emerged as 
new standard of care for this subgroup of patients, which 
accounts for 30% of the overall NSCLC population. 
Conversely, an exploratory analysis of the KEYNOTE-042 
trial  (6),  comparing pembrolizumab to platinum-
chemotherapy in treatment-naive, EGFR/ALK wild-type, 
metastatic NSCLC, with at least 1% of tumor PD-L1 
expression, revealed no survival differences among patients 
with PD-L1 expression between 1% and 49%, with median 
OS of 13.4 vs. 12.1 months (HR 0.92, 95% CI: 0.77–1.11), 
thus questioning the role of single agent immunotherapy in 
the subgroup of patients with intermediate PD-L1 
expression. Recently the results of the phase 3 study 
KEYNOTE-189 (7), comparing pembrolizumab plus 
platinum-pemetrexed followed by pemetrexed and 
pembrolizumab maintenance versus placebo plus 
chemotherapy followed by placebo plus pemetrexed 
maintenance in non-squamous, treatment-naïve, advanced 
NSCLC without EGFR or ALK alterations, revealed the 
superiority of immune-chemotherapy combination even in 
this histological type. This clinical evidence revolutionized 
the old idea that chemotherapy just knocked down the 
pat ient ’s  immune sys tem,  showing as  p la t inum-
combinations may help to trigger the anti-tumor immune 
response, thus increasing immune-checkpoint inhibitors’ 
activity in individual patients. Of note, the clinical benefit 
observed with the addition of pembrolizumab to platinum-
chemotherapy is at the cost of affordable toxicities. Indeed, 
the safety profile observed in the KEYNOTE-407 trial did 
not detach from the expected, being the majority of AEs 
manageable, without new identified toxicities. However, it 
should be noted that the discontinuation rate due to AEs 
nearly doubled in the experimental arm as compared to the 
placebo-arm (13.3% vs. 6.4%, respectively), so that, even if 
this could be partially related to the longer duration of 
treatment, it should be always kept in mind when selecting 
the triplet regimen. A subsequent exploratory analysis of the 
KEYNOTE-407 trial showed that the type of taxane 
(60.1% of patients in the study received paclitaxel, while 
39.9% nab-paclitaxel) did not significantly influence the 
efficacy and safety of immuno-chemotherapy combination, 
revealing an interesting trend toward a longer survival and 
an increased incidence of grade ≥3 AEs in favour of nab-
paclitaxel (8). One of the main raised criticisms concerns 
the study design. Indeed, the control arm included four 
cycles of carboplatin plus taxane, while a maximum of six 
cycles of platinum-chemotherapy is currently recommended 
by all international practice guidelines and represents the 
most adopted strategy in clinical practice. On the other 
side, a recent meta-analysis suggested that four versus six 
cycles of platinum-based first-line chemotherapy led to 
similar OS in advanced NSCLC patients (9), thus limiting 
to four the cycles of chemotherapy could be considered a 
rationale choice. Another limitation of the study design, 
which is common to other upfront chemo-immunotherapy 
combination trials in lung cancer, consists of the impossibility 
to assess whether final OS has been significantly influenced 
by the maintenance therapy with pembrolizumab. A final 
drawback of the current version of the published study is 
the short duration of follow-up (7.8 months), as a 
consequence of a preplanned event-driven, and not time-
driven, second interim analysis, for declaring statistical 
significance. Therefore, long-term efficacy and safety data 
are currently lacking and longer follow-up is eagerly 
expected, especially when dealing with immunotherapy 
AEs, that might emerge even late. Although crossover to 
single agent checkpoint inhibitor for patients enrolled in 
the placebo-group was allowed by protocol design, the 
effective crossover rates were very low, reaching 31.7% in 
the intention-to-treat population and 42.8% among those 
patients who discontinued therapy, with the related causes 
not reported. Therefore, it remains still unclear whether 
combining immune-chemotherapy in first-line would be 
more effective than sequential strategy in squamous 
NSCLC. The percentage of patients receiving immunotherapy 
after platinum-chemotherapy will likely increase with 
additional follow-up, however, if this trend will be 
confirmed, more than half of patients with metastatic 
squamous NSCLC could never receive any second-line 
treatment. As regards the potential benefit of combination 
in patients with central nervous system (CNS) disease, the 
very low number included (20 and 24 patients in 
pembrol izumab- and placebo-combinat ion arms, 
respectively) limited any evidence-based conclusion, 
highlighting a crucial  point that warrant further 
investigation in dedicated trials. With respect to other 
studies, the KEYNOTE-407 interrupted the negative trend 
of upfront combinations in advanced squamous NSCLC, 
suggesting that the PD-1 inhibitor pembrolizumab is the 
best partner to combine with platinum-chemotherapy. 
Indeed, the addition of either ipilimumab (10), or 
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atezolizumab (11), to first-line carboplatin-taxane 
chemotherapy has recently failed to demonstrate any OS 
improvement in a similar naïve, PD-L1 unselected, 
squamous NSCLC population, and the biological, chemical, 
and pharmacological mechanisms underlying these different 
results are hot topics for translational research. Looking for 
immunotherapy predictive biomarkers remain a main 
objective for the academic, scientific community. Although 
the PFS of patients increased accordingly to the tumor PD-
L1 expression levels, no relationship between OS benefit 
and PD-L1 tumor proportion score has been observed in 
this study, thus questioning the usefulness of biomarkers-
based patients’ selection for upfront combinations. Of 
course, the PD-L1 assessment remains crucial to identify 
patients with advanced NSCLC who are candidate to single 
agent pembrolizumab (12). In absence of direct comparison 
data, clinical decision of first-line therapy should be based 
on an individual basis, taking into account both tumor and 
patients’ related characteristics, as well as benefit and risk 
associated to each treatment. Finally, a recent cost-effectiveness 
analysis estimated that the combining immunotherapy and 
chemotherapy will allow to nearly double life expectancy of 
patients with metastatic squamous NSCLC, with an 
incremental cost-effectiveness ratio (ICER) below $100,000/
quality-adjusted life year (QALY), which makes such 
combination a cost-effective first-line option for this 
subgroup of patients (13). 
In conclusion, the study of Paz-Ares et al. represents an 
important step forward in the treatment of patients with 
metastatic squamous NSCLC. Adding pembrolizumab to 
carboplatin-taxane allowed to reach a survival plateau never 
seen before at cost of a modest increase of irAEs, emerging 
as new standard of care for physicians, and more important, 
offering a new hope to a greater number of patients affected 
by this aggressive and difficult to treat disease. Additional 
follow-up of this trial will be crucial to establish the long-
term efficacy and tolerability outcomes and definitively 
confirm first-line immune-chemotherapy combination as 
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